New drug combo targets Hard-to-Treat lung cancer in early trial
NCT ID NCT07489703
First seen Mar 25, 2026 · Last updated Jun 11, 2026 · Updated 14 times
Summary
This study tests a combination of two drugs, SHR-A1811 and ivonescimab, in 30 adults with advanced non-small cell lung cancer that has HER2 abnormalities. The goal is to see if the treatment can slow or stop cancer growth. Participants must have tried at least one prior therapy or be newly diagnosed with HER2-positive disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.